Research graph
References from Case Report: Neuroendocrine-low POU2F3-positive small cell lung cancer presenting as a diagnostically unstable thoracic malignancy. Local targets link to admitted publications; unresolved targets remain external evidence.
Small-cell lung cancer
10.1038/s41572-020-00235-0 · 2021 · External reference
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
10.1038/s41568-019-0133-9 · 2019 · External reference
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
10.1101/gad.314815.118 · 2018 · External reference
SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization
10.1016/j.jtho.2020.09.009 · 2020 · External reference
POU2F3 in SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC
10.1016/j.jtho.2022.06.004 · 2022 · External reference
POU2F3: a sensitive and specific diagnostic marker for neuroendocrine-low/negative small cell lung cancer
10.1097/pas.0000000000002081 · 2023 · External reference
The CARE guidelines: consensus-based clinical case reporting guideline development
10.1136/bcr-2013-201554 · 2013 · External reference
Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset
10.1158/1078-0432.ccr-22-1115 · 2022 · External reference
Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer
10.1002/path.6458 · 2025 · External reference
Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
10.1016/j.annonc.2021.03.207 · 2021 · External reference
Radiation and systemic therapy for limited-stage small-cell lung cancer
10.1200/jco.21.01639 · 2022 · External reference
Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline
10.1016/j.prro.2020.02.009 · 2020 · External reference
Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
10.1056/nejmoa2404873 · 2024 · External reference
Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited-stage small-cell lung cancer
10.1111/1759-7714.14679 · 2022 · External reference
Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial
10.21037/jtd-22-1287 · 2022 · External reference
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
10.1038/s41591-023-02660-6 · 2024 · External reference
Survival analysis of surgical versus nonsurgical treatment in stage I to III small cell lung cancer in the last 20 years: a systematic review and meta-analysis
10.1111/1759-7714.15062 · 2023 · External reference
Consensus statement on ctDNA minimal residual disease testing in early-stage NSCLC: a Delphi study by the Asian Thoracic Oncology Research Group
10.1016/j.jtho.2026.103696 · 2026 · External reference
Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)
10.1158/1078-0432.ccr-21-3044 · 2022 · External reference
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
10.1158/2159-8290.cd-17-0716 · 2017 · External reference
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer
10.1016/j.ccell.2023.08.010 · 2023 · External reference
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
10.1016/j.trecan.2024.04.004 · 2024 · External reference
Cell-free and extrachromosomal DNA profiling of small cell lung cancer
10.1016/j.molmed.2024.08.004 · 2025 · External reference
Molecular subtypes of extra-pulmonary neuroendocrine carcinomas identified by the expression of neuroendocrine lineage-specific transcription factors
10.1007/s12022-022-09722-4 · 2022 · External reference
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer
10.1016/j.ccell.2024.06.012 · 2024 · External reference
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
10.1016/j.ccell.2020.12.014 · 2021 · External reference
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
10.1002/1878-0261.12741 · 2020 · External reference
Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study
10.1002/path.5922 · 2022 · External reference
Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
10.1186/s12957-022-02528-y · 2022 · External reference
